Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Baxter
Farmers Insurance
Daiichi Sankyo
Accenture
Harvard Business School
Covington
Novartis
Citi
US Army

Generated: February 18, 2018

DrugPatentWatch Database Preview

Claims for Patent: 6,776,982

« Back to Dashboard

Summary for Patent: 6,776,982
Title: Autoclavable pharmaceutical compositions containing a chelating agent
Abstract:Disclosed are ophthalmic compositions comprising ketotifen and pharmaceutically acceptable salts thereof, as well as methods for making such compositions.
Inventor(s): Kis; Gyorgy Lajos (Triboltingen, CH), Adam; Marcia Johanna (Gisikon, CH), Fetz; Andrea (Wetzikon, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:10/016,361
Patent Claims: 1. An ophthalmic pharmaceutical composition consisting essentially of 0.0345% ketotifen hydrogen fumarate, 2.125% glycerol, 0.01% benzalkonium chloride and water.

2. The composition according to claim 1 wherein the pH is between about 5.18 and about 5.32.

3. The composition according to claim 1 wherein the osmolality is about 240 milliosmoles.

4. The composition according to claim 2 wherein the osmolality is about 240 milliosmoles.

5. A method for making an ophthalmic pharmaceutical composition, comprising admixing the non-aqueous components ketotifen hydrogen fumarate, glycerol, and benzalkonium chloride with water such that a final concentration of the non-aqueous components is 0.0345% ketotifen hydrogen fumarate, 2.125% glycerol, and 0.01% benzalkonium chloride.

6. The method according to claim 5 wherein the pH of the composition is between about 5.18 and about 5.32.

7. The method according to claim 5 wherein the osmolality of the composition is about 240 milliosmoles.

8. The method according to claim 6 wherein the osmolality is about 240 milliosmoles.

9. The method according to claim 5 wherein the amount of degradation products in said composition is about 0.03%.

10. The composition according to claim 1 wherein the amount of degradation products in said composition is about 0.23%.

11. The composition according to claim 1 wherein the amount of degradation products in said composition is about 0.03%.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Deloitte
Chinese Patent Office
Harvard Business School
Boehringer Ingelheim
Argus Health
Baxter
Daiichi Sankyo
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot